Attached files

file filename
10-Q - 10-Q - Ocera Therapeutics, Inc.tzym10q3q2012.htm
EX-32.1 - EXHIBIT 32.1 - Ocera Therapeutics, Inc.tzymexhibit3213q2012.htm
EX-31.1 - EXHIBIT 31.1 - Ocera Therapeutics, Inc.tzymexhibit3113q2012.htm
EX-31.2 - EXHIBIT 31.2 - Ocera Therapeutics, Inc.tzymexhibit3123q2012.htm
EXCEL - IDEA: XBRL DOCUMENT - Ocera Therapeutics, Inc.Financial_Report.xls


EXHIBIT 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Tranzyme, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard I. Eisenstadt, VP, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
November 9, 2012
By:
/s/ Richard I. Eisenstadt
 
 
 
Richard I. Eisenstadt, VP, Finance and
 
 
 
Chief Financial Officer
 
 
 
(Principal Financial and Accounting Officer)